Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

59.14USD
18 May 2018
Change (% chg)

$0.07 (+0.12%)
Prev Close
$59.07
Open
$58.92
Day's High
$59.46
Day's Low
$57.50
Volume
3,039,971
Avg. Vol
3,720,309
52-wk High
$66.41
52-wk Low
$52.83

Latest Key Developments (Source: Significant Developments)

FDA Issues Alert On Use Of Keytruda/Tecentriq For Patients With Urothelial Cancer, Have Low Expression Of PD-L1
Friday, 18 May 2018 

May 18 (Reuters) - FDA::U.S. FDA - ISSUES ALERT ABOUT DECREASED SURVIVAL ASSOCIATED WITH THE USE OF KEYTRUDA (PEMBROLIZUMAB) OR TECENTRIQ (ATEZOLIZUMAB).U.S. FDA SAYS THERE WAS NO CHANGE IN THE ADVERSE EVENT PROFILE OF KEYTRUDA OR TECENTRIQ.FDA - MERCK, GENENTECH HAVE STOPPED ENROLLING PATIENTS WHOSE TUMORS HAVE PD-L1 LOW STATUS TO KEYTRUDA/TECENTRIQ MONOTHERAPY ARMS PER DMCS’ RECOMMENDATIONS.U.S. FDA SAYS MONOTHERAPY ARMS REMAIN OPEN ONLY TO PATIENTS WHOSE TUMORS HAVE PD-L1 HIGH STATUS.U.S. FDA - COMBINATION ARMS AND THE CHEMOTHERAPY ARMS OF BOTH STUDIES ALSO REMAIN OPEN.FDA - ISSUED ALERT ON KEYTRUDA/TECENTRIQ AS MONOTHERAPY FOR PATIENTS WITH UROTHELIAL CANCER WHO HAVE NOT RECEIVED PRIOR THERAPY, HAVE LOW EXPRESSION OF PD-L1.  Full Article

AstraZeneca Says Lynparza Tablets Receive EU Approval
Tuesday, 8 May 2018 

May 8 (Reuters) - AstraZeneca PLC ::EMA APPROVES LYNPARZA: MAINTENANCE OVARIAN CANCER.LYNPARZA TABLETS RECEIVE EU APPROVAL FOR TREATMENT OF PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER.  Full Article

Merck & Co Says U.S. FDA Has Set PDUFA Date Of Sept. 23, 2018
Monday, 30 Apr 2018 

April 30 (Reuters) - Merck & Co Inc ::FDA GRANTS PRIORITY REVIEW TO MERCK'S SBLA FOR KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH PEMETREXED (ALIMTA®) AND PLATINUM CHEMOTHERAPY BASED ON RESULTS FROM PHASE 3 KEYNOTE-189 TRIAL AS FIRST-LINE TREATMENT OF METASTATIC NONSQUAMOUS NSCLC.MERCK & CO INC - U.S. FDA HAS SET A PDUFA DATE OF SEPT. 23, 2018.  Full Article

Merck & Co Inc Files For Potential Debt Shelf Size Not Disclosed
Thursday, 29 Mar 2018 

March 29 (Reuters) - Merck & Co Inc ::MERCK & CO INC FILES FOR POTENTIAL DEBT SHELF; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer
Monday, 26 Mar 2018 

March 26 (Reuters) - Tesaro Inc ::DATA FROM TOPACIO TRIAL REPORTED AT SGO DEMONSTRATES COMPELLING CLINICAL ACTIVITY OF ZEJULA IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER.TESARO INC - ‍EFFICACY OF NIRAPARIB IN COMBINATION WITH AN ANTI-PD-1 MAB SURPASSES HISTORICAL EFFICACY BENCHMARKS FOR PD-1 OR PARP MONOTHERAPIES​.TESARO INC - COMBINATION OF NIRAPARIB WITH PEMBROLIZUMAB WAS WELL TOLERATED WITH AN INCIDENCE OF GRADE 3/4 THROMBOCYTOPENIA OF 9%.TESARO-POTENTIAL APPROACH TO REDUCE INCIDENCE OF GRADE 3 OR 4 THROMBOCYTOPENIA IDENTIFIED BASED ON RETROSPECTIVE ANALYSIS OF DATA FROM PHASE 3 NOVA TRIAL.TESARO - IN ADDITION TO THROMBOCYTOPENIA, OTHER MOST COMMONLY OBSERVED GRADE ≥3 ADVERSE EVENTS N STUDY INCLUDED ANEMIA AND NEUTROPENIA.  Full Article

Merck Announces Second-Quarter 2018 Dividend
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - Merck & Co Inc ::MERCK ANNOUNCES SECOND-QUARTER 2018 DIVIDEND.MERCK & CO INC - ‍BOARD OF DIRECTORS HAS DECLARED A QUARTERLY DIVIDEND OF $0.48 PER SHARE OF COMPANY'S COMMON STOCK FOR Q2 OF 2018​.  Full Article

Merck says First-Time Data For Keytruda In Patients With Previously Treated Advanced Hepatocellular Carcinoma To Be Presented At 2018 ASCO GI Symposium
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Merck & Co Inc ::FIRST-TIME DATA FOR MERCK'S KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC) TO BE PRESENTED AT 2018 ASCO GI SYMPOSIUM.MERCK & CO INC - SAFETY PROFILE OF KEYTRUDA WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES.MERCK & CO INC - SEVEN PATIENTS DISCONTINUED TREATMENT DUE TO TREATMENT-RELATED ADVERSE EVENTS.MERCK & CO INC - THERE WAS ONE TREATMENT-RELATED DEATH IN THE STUDY.  Full Article

Merck & Co Says Keytruda Phase 3 Keynote-189 Trial Met Its Dual Primary Endpoints
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Merck & Co Inc ::MERCK'S KEYTRUDA(R) (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AS FIRST-LINE TREATMENT IN COMBINATION WITH PEMETREXED AND PLATINUM CHEMOTHERAPY FOR PATIENTS WITH METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER (KEYNOTE-189).MERCK & CO INC - PIVOTAL PHASE 3 KEYNOTE-189 TRIAL MET ITS DUAL PRIMARY ENDPOINTS.MERCK & CO INC - ‍SAFETY PROFILE OF KEYTRUDA IN COMBINATION WAS CONSISTENT WITH THAT PREVIOUSLY OBSERVED​.  Full Article

Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Eisai Co Ltd <4523.T>::EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA® (LENVATINIB MESYLATE) AND KEYTRUDA® (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA.EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA® (LENVATINIB MESYLATE) AND KEYTRUDA® (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA.  Full Article

Merck's Keytruda Significantly Improved Recurrence-Free Survival Compared To Placebo As Adjuvant Therapy
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Merck & Co Inc ::MERCK’S KEYTRUDA® (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED RECURRENCE-FREE SURVIVAL COMPARED TO PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH STAGE 3 RESECTED HIGH-RISK MELANOMA (EORTC1325/KEYNOTE-054).MERCK & CO INC - PHASE 3 EORTC1325/KEYNOTE-054 TRIAL MET PRIMARY ENDPOINT OF RECURRENCE-FREE SURVIVAL.MERCK -SAFETY PROFILE OF KEYTRUDA IN TRIAL WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES INVOLVING PATIENTS WITH ADVANCED MELANOMA.MERCK & CO INC - IN ACCORDANCE WITH TRIAL PROTOCOL, STUDY WILL CONTINUE IN ORDER TO EVALUATE OTHER KEY ENDPOINTS, INCLUDING OVERALL SURVIVAL.  Full Article

Photo

Congo to begin Ebola vaccinations on Monday -health ministry

GOMA, Democratic Republic of Congo Health workers in Democratic Republic of Congo will begin a vaccination campaign on Monday aimed at containing an outbreak of the deadly Ebola virus, a spokeswoman for the health ministry said on Sunday.